Frankfurt - Delayed Quote EUR

BioVaxys Technology Corp. (5LB.F)

Compare

0.0350

0.0000

(0.00%)

As of 8:12:29 AM GMT+1. Market Open.

BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce, further to its news release of January 10, 2025, an extension of its previously announced non-brokered private placement offering of units of the Company (the "Units") at a price of $0.05 per Unit (the "Private Placement"). Each Unit consists of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant

CNW Group 3 days ago

BVAXF
0.00%
BioVaxys Developing DPX to be 'Carrier of Choice' for mRNA Vaccines

BioVaxys Technology (BIOV.CN) on Thursday said it is developing its DPX platform to be the "carrier

PREMIUM
MT Newswires 11 days ago

BIOV.CN
-8.33%
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for its DPX™ non-systemic immune educating platform to address the inherent limitations of lipid nanoparticles ("LNPs") for packaging and delivering mRNA and other polynucleotides. Continued development of DPX-mRNA formulations is one of the Company's objectives, with BioVaxys pursuing collaborations with companies and academic institutions that possess pipelines of promising tu

PR Newswire 11 days ago

BVAXF
0.00%
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 12 days ago

IPWR

NZAUF

ELRRF
BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage company developing a portfolio of vaccines based on its novel DPX™ immune educating platform to treat a range of cancers, infectious diseases, and immune modulated disorders, is pleased to announce that it has been invited to present on the Emerging Growth Conference at 3:25PM - 3:35PM Eastern Time on Thursday January 16, 2025. This live interactive online event will give existing shar

CNW Group 13 days ago

BVAXF
0.00%
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 10,750,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $537,500.

CNW Group 16 days ago

BVAXF
0.00%
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, it has acquired a 48-kilogram ("kg") supply of GMP-grade lipid to enable production of the Company's DPX antigen packaging delivery platform.

PR Newswire last month

BVAXF
0.00%
BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.

CNW Group last month

BVAXF
0.00%
BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.

CNW Group last month

BVAXF
0.00%
BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or pr

CNW Group last month

BVAXF
0.00%
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire last month

UCAR

OPWEF

BIXT
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce that SpayVac for Wildlife, Inc.'s Madison, Wisconsin laboratory and production facility is now fully able to supply its cutting-edge contraceptive vaccines, including its well-established pZP vaccine ("SpayVac®") and its newest GnRH vaccine for commercial aquaculture and other species.

CNW Group 2 months ago

BVAXF
0.00%
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technolo

CNW Group 2 months ago

BVAXF
0.00%
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems.

CNW Group 2 months ago

BVAXF
0.00%
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 2 months ago

VOXR

BVAXF
0.00%
CIA
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Emerging Growth Conference on October 30th, 2024 at 9:40 AM EST. This live interactive online event will give

CNW Group 2 months ago

BVAXF
0.00%
OTC Markets Hosts Virtual Investor Presentation with James Passin, Founder & CEO of BioVaxys Technology Corp, and Brad Sorensen, Senior Analyst at Zacks SCR

OTCQB:BVAXF | CSE:BIOV OTC Markets: Hello and welcome to Virtual Investor Conferences. My name is Cecilia, and on behalf of OTC Markets, as well as our co-host Zacks Small Cap Research, we're very pleased you've joined us for our next live presentation from BioVaxys Technology. Their session will be moderated by Brad Sorensen, Senior Equity Research Analyst with Zacks Small Cap Research. Please

Zacks Small Cap Research 3 months ago

BVAXF
0.00%
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX™ formulations.

CNW Group 3 months ago

BVAXF
0.00%
BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,500,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $225,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchas

CNW Group 3 months ago

BVAXF
0.00%
BIOVAXYS ANNOUNCES CLOSING OF FOURTH TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 3,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $150,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purch

CNW Group 4 months ago

BVAXF
0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioVaxys Technology Corp. (5LB.F)

BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

BioVaxys Developing DPX to be 'Carrier of Choice' for mRNA Vaccines

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENT

BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING

BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024

OTC Markets Hosts Virtual Investor Presentation with James Passin, Founder & CEO of BioVaxys Technology Corp, and Brad Sorensen, Senior Analyst at Zacks SCR

BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor

BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT

BIOVAXYS ANNOUNCES CLOSING OF FOURTH TRANCHE OF PRIVATE PLACEMENT